Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Videos

Richard S. Finn, MD, on Quality of Life With Tislelizumab Versus Sorafenib in HCC Treatment

Tycel J. Phillips, MD, on Administering Glofitamab Monotherapy to Patients With Mantle Cell Lymphoma

Jiye Liu, PhD, on Clinical Implications of Findings on KDM6A as a Modulator of Daratumumab Sensitivity in Multiple Myeloma

Francesco Maura, MD, on Clinical Issues: Resistance in Newly Diagnosed Multiple Myeloma Treated With Targeted Immunotherapy

Sara A. Hurvitz, MD, on Potentially Practice-Changing Findings on T-DXd vs T-DM1 in Metastatic Breast Cancer

Eileen M. Boyle, MD, PhD, on Predicting Treatment Response With Genomic and Immune Microenvironment Features in Multiple Myeloma

Roger Li, MD, on Combining Adenovirus CG007 With Pembrolizumab in Bladder Cancer

Julia Tchou, MD, PhD, on Clinical Implications of Combining a Radiation Boost and Pembrolizumab in Triple-Negative Breast Cancer

Komal Jhaveri, MD, on Clinical Implications of New Data on Neratinib, Fulvestrant, and Trastuzumab for TNBC

Marleen Kok, MD, PhD, on Preoperative Nivolumab for Triple-Negative Breast Cancer: Initial Results From the BELLINI Trial

Ghassan K. Abou-Alfa, MD, on Clinical Implications of Using Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma

Alexander M. Lesokhin, MD, on Initial Safety Data for Elranatamab in Multiple Myeloma

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Ezra E.W. Cohen, MD, on Immunotherapy for Head and Neck Cancer

Sarah A. Holstein, MD, PhD, on Multiple Myeloma: New Induction Therapies

Paul G. Richardson, MD, on Multiple Myeloma: Results From the OPTIMISMM Trial

Adam D. Cohen, MD, on Multiple Myeloma: Findings on CART-BCMA Infusions

Natalie S. Callander, MD, on Newly Diagnosed Multiple Myeloma: What Early-Phase Trials Suggest

Noopur S. Raje, MD, and Kenneth C. Anderson, MD, on Myeloma Bone Disease: Denosumab and Zoledronic Acid

Noopur S. Raje, MD, and Kenneth C. Anderson, MD, on Myeloma Bone: Updated Results on Anti-BCMA CAR T-Cell Therapy

Kenneth C. Anderson, MD, and Francesca M. Gay, MD, on Newly Diagnosed Multiple Myeloma: Results From the FORTE Trial

Bernard J. Escudier, MD, on RCC: How the IMmotion151 Results Could Improve Treatment

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on RCC: Novel Combinations for Advanced Disease

Michael B. Atkins, MD, and Eric Jonasch, MD, on Metastatic Renal Cell Carcinoma: Results From the IMmotion150 Trial

Toni Choueiri, MD, on Newer Agents in the Treatment of Renal Cell Carcinoma

Roy S. Herbst, MD, PhD, on Lung Cancer: Update on Immunotherapy

Tony Mok, MD, on Oncogene-Addicted NSCLC: Expert Perspective on the Challenges

Ramaswamy Govindan, MD, and Jaafar Bennouna, MD: Results From the AvaALL Trial

Stephanie Andrews, MS, ANP-BC, on Managing Toxicities of Immunotherapies

Daniel R. Gomez, MD, on Immunotherapy in Lung Cancer and the Value Proposition

Walter J. Curran, MD, on Stage III NSCLC

Naiyer A. Rizvi, MD, on Immunotherapy: Beyond Checkpoint Inhibition

Michael A. Postow, MD, on Immunotherapy for Melanoma: Expert Perspective

Drs. Coit and Shoushtari on Melanoma: The Team Approach to Managing Toxicities of Checkpoint Inhibitors

Alexander N. Shoushtari, MD, on Dosing Nivolumab

Alexander N. Shoushtari, MD, on Toxicities of Nivolumab

Sunandana Chandra, MD, on Advanced Melanoma: Targeted and Immunotherapies for Brain Metastases

Georgina V. Long, MD, PhD, on Metastatic Melanoma: Results of the Anti–PD-1 Brain Collaboration

Hussein Tawbi, MD, PhD, and John A. Thompson, MD, on Melanoma: Results From the CheckMate 204 Trial

Anthony J. Olszanski, RPh, MD, and John A. Thompson, MD, on Advanced Melanoma: Novel Treatment Approaches in Two Settings

Glenn Hanna, MD, on Using Checkpoint Inhibitors for Head and Neck Cancer

Danny Rischin, MD, on Cemiplimab for Metastatic Squamous Cell Carcinoma

Silvia Formenti, MD, on Combining Immunotherapy and Radiation Therapy

Mark G. Kris, MD, on NSCLC: Juggling Sequence and Agent Choices in Lung Cancer

Leora Horn, MD, on NSCLC: The Path Forward for ALK Inhibitors and Immunotherapy

Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy Perspectives

Roisin M. Connolly, MD, on Yearly Review of Breast Cancer Treatment Advances

Marleen Kok, MD, PhD, on Luminal Breast Cancer: Immunotherapy Strategies

Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on Immunotherapy for TNBC: IMpassion130 Results

Andrew D. Seidman, MD, and Aditya Bardia, MD, MPH, on Use of Sacituzumab Govitecan in Metastatic Breast Cancer

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Trial Results of IMMU-132

G. Thomas Budd, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

William J. Gradishar, MD, and Rita Nanda, MD, on High-Risk Breast Cancer: Results From the I-SPY 2 Trial

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

William J. Gradishar, MD, on Triple-Negative Breast Cancer: Expert Perspective on the KEYNOTE-086 Trial Results

Hope S. Rugo, MD, on Locally Recurrent or Metastatic Breast Cancer: Results of a CALGB/NCCTG Trial

Helena Margaret Earl, MBBS, PhD, on Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial

Kathleen Colson, RN, BSN, BS, on Preventing Infusion Reactions to Daratumumab

Martin Reck, MD, PhD, on Selecting Immunotherapy

Cristina Saura, MD, on Choosing Neoadjuvant Treatment for Patients With Early Breast Cancer

Shaji Kumar, MD, and Prashant Kapoor, MD, on BCL2 Inhibition for the Treatment of Resistant Multiple Myeloma

Martin Reck, MD, PhD, on NSCLC: Results From Three Key Trials

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Administering Daratumumab

Ruth M. O’Regan, MD, and Douglas Yee, MD: Results From the I-SPY2 Trial

David Siegel, MD, PhD, on Relapsed / Refractory Multiple Myeloma: Final Results From the ASPIRE Trial

Luis G. Paz-Ares, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

Virginie Westeel, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

Natalie S. Callander, MD, on Multiple Myeloma: Cost Effectiveness of Drugs Used to Treat Relapsed/Refractory Disease

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Sumanta K. Pal, MD: Interpreting the Latest Results From the COSMIC-021 Study on Cabozantinib Plus Atezolizumab in Urothelial Carcinoma

Shanu Modi, MD, on Clinical Implications of New Findings on T-DXd for Metastatic Breast Cancer

Monika Joshi, MD, on Findings on Chemoradiation With Durvalumab in Urothelial Carcinoma

Karen L. Reckamp, MD, on Ramucirumab Plus Pembrolizumab for NSCLC: Practical Clinical Considerations

Hope Rugo, MD, on Clinical Implications of New Findings on the Benefits of Sacituzumab Govitecan-hziy in Advanced Breast Cancer

Erika Hamilton, MD, on T-DXd for Metastatic Breast Cancer: Clinical Considerations

Jonathan E. Rosenberg, MD, on Enfortumab Vedotin-ejfv vs Chemotherapy in Urothelial Cancer: Practical Clinical Considerations

Won Seog Kim, MD, PhD: Early Results on Anbalcabtagene Autoleucel for Large B-Cell Lymphoma

Michael Dickinson, MBBS, on Clinical Implications of New Findings on Glofitamab for DLBCL

Axel Bex, MD, PhD, on Avelumab and Axitinib for Renal Cell Carcinoma: Findings From the NeoAvAx Trial

Petros Grivas, MD, PhD, on Update on Treatment With Sacituzumab Govitecan-hziy and Pembrolizumab in Urothelial Cancer

Matthew R. Zibelman, MD, on New IO/TKI Combination Under Study in Kidney Cancer

Toni K. Choueiri, MD, on Long-Term Data From KEYNOTE-564 on Pembrolizumab as Adjuvant Therapy for Kidney Cancer

Sara A. Hurvitz, MD, on the DESTINY-Breast03 Trial: T-DXd Versus T-DM1 for HER2+ Breast Cancer

Charles Coombes, MD, PhD, on Clinical Implications of Using Samuraciclib With Fulvestrant for HR–Positive HER2–Negative Breast Cancer

Jonathan E. Rosenberg, MD, on Clinical Implications of New Findings on Durvalumab Plus Olaparib for Stage IV Urothelial Cancer

Daniel P. Petrylak, MD, on Enfortumab Vedotin-ejfv as Monotherapy for Bladder Cancer

Javier Cortés, MD, PhD, on Clinical Interpretation: First-Line Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer

Peter Schmid, MD, PhD, on a Possible Practice-Changing Regimen for Patients With Early-Stage, High-Risk TNBC

Leo I. Gordon, MD, on Using CAR T-Cell Therapy Earlier for DLBCL: Time to Change the Standard of Care?

Manali Kamdar, MD, on Clinical Implications of New Findings on Lisocabtagene Maraleucel in Large B-Cell Lymphoma

Roni Shouval, MD, PhD, on Clinical Implications of New Findings on TP53, Large B-Cell Lymphoma, and CAR T-Cell Therapy

Stephanie T. Schmidt, PhD, on Neoadjuvant Chemotherapy and Immune-Based Treatments in NSCLC

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Study Results on Retifanlimab

Hannah E. Dzimitrowicz, MD: Is the COVID-19 Vaccine Safe and Effective for Patients With Kidney Cancer?

Hope S. Rugo, MD, on Immunotherapy Combinations for Breast Cancer

Roger Li, MD, on Bladder Cancer: A Possible New Treatment in CG0070 Plus Pembrolizumab

Hope S. Rugo, MD, on KEYNOTE-355 Findings on Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer

Helena M. Earl, MBBS, PhD: Is a Shorter Duration of Trastuzumab Effective in Early-Stage HER2-Positive Breast Cancer?

Thomas Powles, MD, PhD, on Clinical Implications of the NORSE Trial: Erdafitinib Plus Cetrelimab in FGFR-Altered Advanced Urothelial Carcinoma

Toni K. Choueiri, MD, on Quality-of-Life Outcomes Reported in KEYNOTE-564 by Patients With RCC

Nasser K. Altorki, MD: Expert Perspective on the IMpower010 Study of Atezolizumab for NSCLC

Naveen S. Vasudev, PhD, MBChB, on Ipilimumab Plus Nivolumab for RCC: Duration of First-Line Treatment

Javier Cortés, MD, PhD: Clinical Insights on Using Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

Saad Z. Usmani, MBA, MD: Expert Perspective on the Use of Ciltacabtagene Autoleucel in Multiple Myeloma

Paul G. Richardson, MD, on Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone in Multiple Myeloma

Efstathios Kastritis, MD: A New Standard of Care for Amyloidosis in Multiple Myeloma?

Peter H. O’Donnell, MD, on Pembrolizumab for Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

Sibylle Loibl, MD, PhD, on Adding Durvalumab to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Niels van de Donk, MD, PhD, on Early Results on Teclistamab as a Future Treatment Option for Multiple Myeloma

Martin Reck, MD, PhD, on Dual Immunotherapy Plus Chemotherapy: A Better Way to Treat NSCLC Than Chemotherapy Alone?

Matt D. Galsky, MD, on Predicting Which Patients With Bladder Cancer Given Neoadjuvant Therapy May Avoid Cystectomy

Larry D. Anderson, Jr, MD, PhD, on Idecabtagene Vicleucel CAR T-Cell Therapy in Multiple Myeloma

Alexander C. J. van Akkooi, MD, PhD, on Domatinostat Plus Avelumab for Merkel Cell Carcinoma

Nadia Harbeck, MD, PhD: Expert Perspective on De-escalating Breast Cancer Therapy With Paclitaxel, Pertuzumab, and Trastuzumab

Brian I. Rini, MD, on Clinical Implications of Treatment With Pembrolizumab Plus Axitinib for RCC

Toni K. Choueiri, MD, on KEYNOTE-564: Pembrolizumab in the Adjuvant Treatment of Renal Cell Carcinoma

Heather A. Wakelee, MD, on Clinical Implications of Treating NSCLC With Atezolizumab

Brian I. Rini, MD, on Using Biomarkers to Inform Treatment Decisions in Renal Cell Carcinoma

Enrique Grande, MD, PhD, on Results From IMvigor130: Atezolizumab Plus Platinum-Based Chemotherapy for Urothelial Cancer

Melinda L. Telli, MD, on Choosing Among Many Treatment Options for HER2-Positive Breast Cancer

Toni K. Choueiri, MD, on Selecting Treatment for Advanced Kidney Cancer: Findings From the CLEAR Trial

William J. Gradishar, MD, on Updated NCCN Guidelines: Treatment Approaches and Research in Triple-Negative Breast Cancer

Arlene O. Siefker-Radtke, MD, on Comparing Immunotherapy and Antibody-Drug Conjugates for Urothelial Bladder Cancer

Tracy L. Rose, MD, on Clinical Implications of Treating Bladder Cancer With Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab

Thomas Powles, MD, PhD, on Enfortumab Vedotin-ejfv: New Standard of Care for Aggressive Urothelial Carcinoma?

Rana R. McKay, MD, on the Treatment Landscape for Metastatic RCC

Monika Joshi, MD, on After the DUART Trial: Next Steps in Treating Urothelial Cancer of the Bladder

Martin Reck, MD, PhD, on Monotherapy vs Combination Treatment for High PD-L1–Expressing NSCLC: Expert Perspective

Thomas Powles, MD, PhD: A Look Into the Future of Kidney Cancer Treatment

Ziad Bakouny, MD, on Sarcomatoid and Rhabdoid RCC: Response to Immune Checkpoint Inhibitors

David A. Braun, MD, PhD, on Immunogenomics and Immunotherapy in Renal Cell Carcinoma

Rana R. McKay, MD, on Nivolumab and Ipilimumab in Advanced Kidney Cancer

Sara A. Hurvitz, MD, on Evaluating Biomarkers in Triple-Negative Breast Cancer

Sagar Lonial, MD, on Clinical Implications of New Data on CAR T-Cell Treatments for Multiple Myeloma

Shailender Bhatia, MD, on Pembrolizumab in Front-Line Treatment of Merkel Cell Carcinoma

Jonathan E. Rosenberg, MD, on Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Nadia Harbeck, MD, on Trastuzumab Emtansine and Pertuzumab vs. Trastuzumab, Pertuzumab, and Taxane After Anthracyclines in Early Breast Cancer

Thomas Flaig, MD, on Advances in Bladder Cancer Treatment: Expert Perspective

Thomas Flaig, MD, on NCCN Clinical Practice Guidelines in Oncology®: Their Increasing Importance in Bladder Cancer

Aristotelis Bamias, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy

Aditya Bardia, MD, MPH, on Clinical Implications of Prescribing Sacituzumab Govitecan for Triple-Negative Breast Cancer

Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Clinical Implications of Findings on Paclitaxel and Atezolizumab

Benjamin Besse, MD, PhD, on Clinical Tips for Prescribing Atezolizumab as Neoadjuvant Therapy for Resectable NSCLC

Matthew S. Davids, MD, on Sequence of Administration of Ibrutinib Plus Obinutuzumab for CLL

Misako Nagasaka, MD, on Sintilimab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

Elizabeth H. Stover, MD, PhD, on Nivolumab and Bevacizumab: Genomic Biomarker Analysis of an Ovarian Cancer Regimen

Shaji Kumar, MD, and Prashant Kapoor, MD: Update on CAR T-Cell Therapies for Multiple Myeloma

Paul G. Richardson, MD, on a Novel Immunotherapy Plus Dexamethasone in Relapsed or Refractory Myeloma

Egbert F. Smit, MD, PhD, on Clinical Implications of Fam-trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Danny Rischin, MD, on Cutaneous Squamous Cell Carcinoma: Follow-up Data on Cemiplimab

Lucy Gilbert, MD, on Mirvetuximab Soravtansine Plus Bevacizumab for Platinum-Agnostic Ovarian Cancer

Nikolaos Andreatos, MD, on Adverse Events Following Radiotherapy and Immunotherapy in Patients With Melanoma and Merkel Cell Carcinoma

Suresh S. Ramalingam, MD, on Clinical Implications of Using Nivolumab Plus Ipilimumab in First-Line NSCLC

Prashant Kapoor, MD, and Shaji Kumar, MD, on Bortezomib, Lenalidomide, Dexamethasone With or Without Elotuzumab for Multiple Myeloma

Scott Kopetz, MD, PhD, on BEACON CRC: Combination Regimen for Metastatic Colorectal Cancer

Thierry André, MD, on KEYNOTE-177: Clinical Implications of Pembrolizumab vs Chemotherapy in Metastatic Colorectal Cancer

Nancy U. Lin, MD, on the HER2CLIMB Trial: Triplet Regimen for Metastatic Breast Cancer

Theresa L. Werner, MD, on Ovarian Cancer and the Immunotherapy Revolution

Steven J. O’Day, MD, on Activating Innate Immunity in Triple-Negative Breast Cancer and Other Tumors

Christopher Sweeney, MBBS, on Prostate Cancer: IMbassador250 Trial on Atezolizumab and Enzalutamide

Lajos Pusztai, MD, PhD: Update on Triplet Regimen for High-Risk HER2-Negative Breast Cancer

Scott Kopetz, MD, PhD, on ANCHOR vs. BEACON: Identifying the Optimal Setting for Treatment

Nadeem Riaz, MD, on Immunotherapy Biomarkers in Head and Neck Cancer: Guiding Treatment Decisions

Julie N. Graff, MD, on Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant Metastatic Castration-Resistant Disease

Jared Weiss, MD, on Integrating Radiotherapy With Immune Checkpoint Inhibitor Treatment

Sara M. Tolaney, MD, MPH, on Immunotherapy for Breast Cancer: Moving Into Early-Stage Disease

Nizar M. Tannir, MD, on Nivolumab Plus Ipilimumab vs Sunitinib: Choosing Therapy and Managing Toxicities

Thibaud Kössler, MD, PhD, on Neoadjuvant Immunotherapy and Radiotherapy in MSS Rectal Cancer

Heinz-Josef Lenz, MD, on Reducing Ipilimumab Dose: What Are the Ramifications?

Luca Gianni, MD, on Evaluating Progress With Checkpoint Inhibitors in Breast Cancer

Javier Cortes, MD, PhD, on Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer

C. Ola Landgren, MD, PhD, on Managing a Complex Four-Agent Regimen in Myeloma

Tait D. Shanafelt, MD, on Comparing Toxicities of New and Standard Treatments for CLL

Saad Z. Usmani, MD, on The Challenges of Administering a New Triple Regimen in Myeloma

Karl D. Lewis, MD, on Selecting Patients for Treatment With Cemiplimab-rwlc

Solange Peters, MD, PhD, on Managing Toxicities of Checkpoint Inhibitors and Chemotherapy Regimens in NSCLC

Ana Maria Arance Fernandez, MD, PhD, on Melanoma Treatment in Light of the IMspire170 Trial

Peter Schmid, MD, PhD, on The Future of Checkpoint Inhibitors in the Neoadjuvant Setting

Isabelle Ray-Coquard, MD, PhD, on the Safety of Combination Regimens With Bevacizumab

Theresa M. Medina, MD, on Basal Cell Carcinoma and Immunotherapy

Karl D. Lewis, MD, on the Role of Adjuvant Immunotherapy in NMSC

Andreas Rimner, MD, on Consolidation Therapy With Durvalumab in Later-Stage Lung Cancer

Theresa M. Medina, MD, on Treating Cutaneous Squamous Cell Carcinoma With Cemiplimab-rwlc

Jennifer R. Brown, MD, PhD, on Using Venetoclax and Rituximab in Chronic Lymphocytic Leukemia

Jennifer R. Brown, MD, PhD, on Treating CLL With the Novel Immunotherapy KTE-X19

Ian W. Flinn, MD, PhD, on Chronic Lymphocytic Leukemia: Early-Phase Research on Immunotherapy

Vatche Tchekmedyian, MD, on Adenoid Cystic Carcinoma: Treatment With Nivolumab and Ipilimumab

William G. Wierda, MD, PhD, on Clinical Implications of Experimental CAR T-Cell Treatment in Relapsed/Refractory CLL/SLL

Peter Schmid, MD, PhD: Update on IMpassion130: Use of Doublet to Treat Triple-Negative Breast Cancer

Matteo Lambertini, MD, PhD, on Atezolizumab in Triple-Negative Breast Cancer

Daniel P. Petrylak, MD, on Supporting Patients Considering a Clinical Trial

Thomas Powles, MD, PhD, on Using Nivolumab and Ipilimumab in Renal Cell Carcinoma

Paul G. Richardson, MD, on Using Elotuzumab After Initial Therapy for Multiple Myeloma

Suresh S. Ramalingam, MD, on Comparing Maintenance Therapies in Non–Small Cell Lung Cancer: Less May Be More

Francesca Gay, MD, on Using Elotuzumab to Treat Multiple Myeloma

Hope S. Rugo, MD, on Using Margetuximab in the Community Setting for HER2-Positive Metastatic Breast Cancer

Mansoor Raza Mirza, MD, on the Potential Role of PARP Inhibition Plus Immunotherapy in Ovarian Cancer

Jonathan E. Rosenberg, MD, on Clinical Implications of Adding Bevacizumab to Gemcitabine/Cisplatin in Urothelial Carcinoma

Yoland C. Antill, MD, on the Potential Role for Durvalumab in Treating Advanced Endometrial Cancer

William J. Gradishar, MD, on Atezolizumab and Nab-paclitaxel in Triple-Negative Breast Cancer

Danny Rischin, MD, on Potential New Standards of Care in Head and Neck Squamous Cell Carcinoma

Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Combining Checkpoint Inhibitors With Targeted Treatment

Ahmad A. Tarhini, MD, PhD, on Survival Benefits of Adjuvant Ipilimumab in High-Risk Melanoma

Paul G. Richardson, MD, on a New Triplet Therapy in Relapsed/Refractory Multiple Myeloma

David J. Kwiatkowski, MD, PhD, on Clinical Implications of Neoadjuvant Atezolizumab for Resectable Non–Small Cell Lung Cancer

Daniel P. Petrylak, MD, on Toxicities in Nivolumab or Ipilimumab for Urothelial Cancer

Lara Dunn, MD, on Managing Immunotherapy Adverse Events in Head and Neck Cancer

Leora Horn, MD, on Managing the Adverse Events of Combination Therapies

Chrysalyne Schmults, MD, on Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma: Treatment Pipeline

Anthony J. Olszanski, MD, RPh, on Cutaneous Melanoma: Adjuvant Systemic Therapy

David S. Ettinger, MD, and Matthew A. Gubens, MD: Immunotherapies for Lung Cancer

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: Reducing the Frequency of Nivolumab Dosing

Nicolas Guibert, MD, PhD, on Non–Small Cell Lung Cancer: Clinical Implications of Using a New Algorithm to Predict Response to Immunotherapy

Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Predicting Survival Outcomes

Shirish M. Gadgeel, MD, on Advanced Non–Small Cell Lung Cancer: Integrating Chemotherapy and Immunotherapy

Matthew A. Gubens, MD, on Non–Small Cell Lung Cancer: Is There Still a Role for Chemotherapy?

Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Expert Perspective

G. Travis Clifton, MD, on Breast Cancer: Using a Cancer Vaccine With and Without Trastuzumab to Prevent Recurrences

Rana R. McKay, MD, on Renal Cell Carcinomas: The Potential Role for Atezolizumab and Bevacizumab

Nicholas Vogelzang, MD, on Urothelial Cancer: Lenvatinib Plus Pembrolizumab

Hans C. Lee, MD, on Administering Daratumumab

Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.